A new class of antibiotic candidates against MRSA
A deep-learning model trained on about 39,000 compounds screened about 12 million commercial compounds; of about 280 purchased and tested, two from the same class reduced MRSA burden tenfold in two mouse models, with very low toxicity to human cells. Results from plates and mice; toxicity was partly predicted computationally.
Technology: Deep learning with chemical-structure explainability
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: About 283 compounds were bought and tested empirically; one structural class reduced bacterial burden in mouse skin and systemic thigh infection models, and cytotoxicity to human cells was measured.
- Still unknown: The page does not list specific study limitations; next steps are chemical property analysis and potential clinical use.
- AI role: Graph neural network ensembles trained on about 39,000 compounds with measured antibacterial and human-cell toxicity predicted both properties for about 12 million compounds and flagged candidates for purchase and testing.
Evidence sources: https://news.mit.edu/2023/using-ai-mit-researchers-identify-antibiotic-candidates-1220 · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41586-023-06887-8&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 538 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.